Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 298

The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.

Therapies targeting DNA and RNA in Huntington's disease

Open access
Wild, Edward J, Tabrizi, Sarah J·2017·The Lancet Neurology

Abstract

Summary No disease-slowing treatments exist for Huntington’s disease (HD), but its monogenic inheritance makes it an appealing candidate for the development of therapeutics targeting pathogenic processes close to its root genetic cause. HD is caused by CAG repeat expansions in the HTT gene, which encodes huntingtin protein; targeting of HTT transcription and the translation of its mRNA are therefore an area of intense investigation. ‘Huntingtin-lowering’ strategies include antisense oligonucleotides (ASOs) and RNA interference compounds targeting mRNA; and zinc-finger transcriptional repressors (ZFTR) and newer CRISPR/Cas9 methods aiming to reduce transcription by targeting DNA. An intrathecally-delivered ASO targeting total huntingtin is now well into its first human clinical trial, with other ASO approaches expected to enter trials within the next 1-2 years, and virally-delivered RNAi and ZFTR in advanced testing in animal models. Meanwhile, recent advances to improve the design and delivery of targeted therapeutics are likely to improve their efficacy, safety, tolerability and duration of effect.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(17)30280-6

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 71 references

Cited by

See all 298

Metadata

Authors
Wild, E. J., & Tabrizi, S. J.
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2017-10
Volume
16
Issue
10
Pages
837-847
ISSN
1474-4422 (ISSN-L)
OpenAlex
W2755227731
Cited by
298
References
71
FWCI
14.91
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Therapies targeting DNA and RNA in Huntington's disease. https://app.cochat.ai/papers/10.1016/s1474-4422(17)30280-6
The paper
Wild, E. J., & Tabrizi, S. J. (2017). Therapies targeting DNA and RNA in Huntington's disease. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(17)30280-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.